From Brewing Sake to Brewing Science: Takara Bio’s Bold New Chapter with CSO Andrew Farmer

How Pathologists Can Lead in Precision Medicine with David Braxton

From DNA to Proteins: Illumina Makes Its Proteomics Play - with Krishna Morampudi

Theranos Had the Vision. Truvian Has the Execution. Our Chat with CEO Jay Srinivasan

Physicians Don't Want a Laundry List of Genes says Premal Shah, CEO of Myome

The Customer Case for iconPCR with Stefan Green and Yann Jouvenot

Alex Dickinson on Long Read Sequencing, Multi Omics, and the Next Frontier in Genomics

Rapid Answers for Rare Disease: Katherine Stueland on GeneDx’s Mission

Moran Snir's Vision for Making Genomic Care Routine across the U.S.

How Certis Is Rewriting Cancer Models with CEO Peter Ellman

Myriad’s Next Chapter: New CEO Sam Raha on Growth, AI, and MRD Testing

Next-Gen MRD Testing: Foresight’s Leap in Sensitivity with Jake Chabon and Dave Kurtz

Bodour Salhia and Danielle Goldberg: Rethinking Cancer Research with Illumina's 5-Base Solution

Reinventing PCR: Pranav Patel, N6 Tec

Making Whole Genome Sequencing the Universal Genetic Test - with David Ledbetter, Pediatric Rare Disease Institute, FSU

Remembering Atul Butte with Marina Sirota, Chirag Patel and Mike Snyder

The Age of Digital Pathology with Andy Beck, PathAI

What’s New for Regulatory Informatics in the Age of AI? Not Much—And That’s the Point with Raju Rayavarapu of DNAnexus

From Illumina to Advocacy: Mike Kreitzinger on the Future of Clinical Genomics

Amplifying the Expert: Jing Gao on Illumina's Connected Insights